Collegium Pharmaceutical (COLL) PT Lowered to $48 at Barclays
Tweet
Share
E-mailGet Alerts COLL Hot Sheet
Price: $23.04 +1.19%
Rating Summary:
9 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 28
Rating Summary:
9 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 28
Join SI Premium – FREE
Barclays analyst Glen Santangelo lowered the price target on Collegium Pharmaceutical (NASDAQ: COLL) to $48.00 (from $56.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Adeptus Biotechnologies Corp. (ADPT) PT Raised to $34 at BTIG
- Delek Logistics Partners, LP (DKL) PT Raised to $57 at UBS
- Kymera Therapeutics (KYMR) PT Raised to $152 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
